Annexon Inc (ANNX) - Total Liabilities
Based on the latest financial reports, Annexon Inc (ANNX) has total liabilities worth $58.35 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Annexon Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Annexon Inc's total liabilities have evolved over time, based on quarterly financial data. See ANNX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annexon Inc Competitors by Total Liabilities
The table below lists competitors of Annexon Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou Longway Electronic Machinery Co. Ltd. A
SHE:301202
|
China | CN¥741.06 Million |
|
Jiangsu Tongli Risheng Machinery Co. Ltd.
SHG:605286
|
China | CN¥2.63 Billion |
|
GHT Co Ltd Class A
SHE:300711
|
China | CN¥481.99 Million |
|
BEIJ.JINGNENG CL.ERG.HYC1
F:BJ6
|
Germany | €64.73 Billion |
|
Golden Entertainment Inc
NASDAQ:GDEN
|
USA | $601.89 Million |
|
Movida Participações S.A
SA:MOVI3
|
Brazil | R$32.88 Billion |
|
National Grid PLC
LSE:NG
|
UK | GBX66.54 Billion |
|
Brightspire Capital Inc
NYSE:BRSP
|
USA | $2.74 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Annexon Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Annexon Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Annexon Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Annexon Inc (2017–2025)
The table below shows the annual total liabilities of Annexon Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $65.92 Million | +15.72% |
| 2024-12-31 | $56.97 Million | +20.90% |
| 2023-12-31 | $47.12 Million | -12.59% |
| 2022-12-31 | $53.90 Million | -2.23% |
| 2021-12-31 | $55.13 Million | +372.50% |
| 2020-12-31 | $11.67 Million | +83.23% |
| 2019-12-31 | $6.37 Million | -37.99% |
| 2018-12-31 | $10.27 Million | -80.99% |
| 2017-12-31 | $54.03 Million | -- |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more